mTOR inhibitorFDA-approvedSecond-line
Everolimus
How it works
Blocks the mTOR enzyme, which is involved in cell growth and division, thereby inhibiting cancer cell growth.
Cancer types
Breast Cancer— HER2-positive
Efficacy
Studies show that patients with hormone receptor-positive breast cancer who received everolimus in combination with exemestane had improved progression-free survival compared to those who received exemestane alone.
Side effects
Severe
This treatment carries a higher risk of serious side effects. Close medical monitoring is required throughout treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Everolimus Effectiveness in Rare Tumors Varies by Genetic Pathway | Pancreatic Cancer | observational | Alterations in the PI3K/AKT/mTOR pathway were associated with a higher disease control rate (85.7% vs. 28.6%); | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.